Merck & Co., Inc. (MRK)
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck (MRK) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Merck's Stock Dip Offers a Buying Opportunity: Here's Why
Global big pharmaceutical company Merck & Co. Inc. NYSE: MRK shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024 guidance sank the stock.
Buying Wonderful Businesses At Fair Prices - The Billionaire Way
Warren Buffett's success stems from evolving his strategy to focus on buying high-quality businesses at fair prices rather than just seeking deep-value investments. By deeply understanding businesses and investing with conviction, Buffett minimizes diversification and adopts an ownership mindset for long-term gains. Applying Buffett's principles, I explore three strong investment opportunities with solid growth potential, emphasizing quality, profitability, and attractive valuations.
Merck: Buy This Bargain Before It's Gone
Despite Merck beating analysts' expectations for the second quarter of 2024, its stock price fell 9%. The company's stock sell-off came as a result of an unexpected decline in sales of the Gardasil franchise in China and a cut in its forecast for full-year adjusted EPS. On the other hand, sales of Merck's oncology franchise totaled about $8.05 billion, up 16.4%, thanks to solid sales of Keytruda, its key blockbuster.
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
On Friday, Merck & Co Inc MRK agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billion
Merck said Friday it's has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck says it's discontinuing a late-stage trial of a lung cancer treatment after high number of adverse events
Merck & Co. MRK, +1.21% said Thursday it's discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events. The company said it's notifying study investigators of the decision and telling them patients should stop treatment, which was a fixed dose of vibostolimab, an anti-TIGIT antibody, and pembrolizumab, or Keytruda, Merck's blockbuster cancer drug, in combination with chemotherapy compared to atezolizumab in combination with chemotherapy.
Merck stops experimental lung cancer drug combo trial
Merck said on Thursday it had discontinued its trial of a combination of its experimental drug and blockbuster therapy Keytruda for the treatment of a type of lung cancer, after an interim analysis showed the drug was unlikely to succeed.
The 3 Best Biotech Stocks to Buy in August 2024
Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.
